55 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Immunotherapy
  • Therapy
  • Germany
  • Product Initiative
  • Anergis SA

The goal was to demonstrate safety and efficacy of recombinant Bet v ## for desensitization against birch pollen allergy.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Anergis SA

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Therapy
  • United States
  • World
  • Product Initiative

House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H## 2019 ZHEJIANG I-BIOLOGICAL TECHNOLOGY CO LTD House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUS

  • Medical Biotechnology
  • Therapy
  • World
  • Product Initiative
  • Anergis SA

Vaccine ## for Grass Pollen Allergy - Drug Profile Vaccine for Grass Pollen Allergy - Drug Profile Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Vaccine for Grass Pollen Allergy DC##U B

  • Allergy
  • Immunotherapy
  • Therapy
  • United States
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Therapy
  • United States
  • Aimmune Therapeutics, Inc.

About ## percent of people who have food allergies are allergic to more than one food.

  • Medical Biotechnology
  • Therapy
  • Japan
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Immunotherapy
  • Therapy
  • United States
  • Product Initiative

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Chronic Disease
  • Therapy
  • United States
  • Product Initiative

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Therapy
  • Japan
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Therapy
  • United States
  • Aimmune Therapeutics, Inc.

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Medical Biotechnology
  • Therapy
  • United States
  • World
  • Product Initiative

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Therapy
  • United States
  • World
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • Product Initiative

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Pharmaceutical
  • Research And Development
  • Therapy
  • AstraZeneca PLC

These drugs are useful for treatment of inflammatory diseases, allergy, pain, , asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria etc.

  • Therapy
  • United States
  • World
  • Product Initiative
  • Sensorion S.A.

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Therapy
  • China
  • United States
  • Product Initiative
  • Helsinn Group

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Blood Disease
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Sensorion S.A.

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy
  • Therapy
  • United States

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • Allergy Therapeutics plc

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Chronic Disease
  • Therapy
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

Adults with HAE Type I or II self-administered a dose of blinded study drug for three attacks; two treated with active drug and one with placebo, in a randomized sequence.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • BioCryst Pharmaceuticals, Inc.

The drug candidate acts by blocking the histamine receptors and prevents the excess mucus production associated with ocular allergy.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostics
  • Therapy
  • Sensorion S.A.

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Pharmaceutical
  • Therapy
  • Canada
  • United States
  • Product Initiative